A mechanism related to antidepressant use may reduce the hazard of eventual Alzheimer disease (AD), according to a recent study. Furthermore, the findings reinforce the association between depression, apolipoprotein E (APOE) ε4, and AD diagnosis. Utilizing data from the National Alzheimer's Coordinating Center, researchers examined evaluations of 11,443 cognitively intact participants. Survival analysis was used to explore relationships between depression, apolipoprotein E, AD diagnosis, and antidepressant use. They found:
- An analytical sample of 8,732 participants with normal cognition was examined.
- Among users of antidepressant medication, the hazard, in most cases, was no longer statistically significant.
- 1 generic medication showed protective benefits for users.
- In addition, there was a statistically significant relationship between recent depression (n=2,083), lifetime depression (n=2,068), and ε4 carrier status (n=2,470) and AD development.
Burke SL, Maramaldi P, Cadet T, Kukull W. Decreasing hazards of Alzheimer's disease with the use of antidepressants: Mitigating the risk of depression and apolipoprotein E. [Published online ahead of print May 31, 2017]. Int J Geriatr Psychiatry. doi:10.1002/gps.4709.